The Efficacy of Hemp-containing Cream Versus Placebo in the Treatment of Uremic Pruritus
Status:
Completed
Trial end date:
2023-12-08
Target enrollment:
Participant gender:
Summary
Uremic pruritus is a significant burden on hemodialysis patients, affecting approximately 46%
of individuals undergoing dialysis. Various mechanisms, including inadequate dialysis,
increased uremic toxins, inflammatory cytokines, parathyroid hormone, phosphorus, dry skin,
mast cell histamine secretion, and nerve stimulation through μ-opioid receptors and
nociceptors, contribute to uremic pruritus. Current treatments include antihistamines,
gabapentin, moisturizer creams, and capsaicin creams, with limited success, as only 10% of
patients find relief. Cannabinoids were also mentioned in uremic pruritus treatment but are
less commonly used and there are no randomised controlled trial. Cannabinoid binding to CB1
and CB2 receptors inhibits mast cell differentiation, aggregation, and histamine release,
whereas cannabinoid binding to TRP-iron receptors reduces peripheral nerve activation. Thus,
cannabinoid seem to effective in relieving pruritus via various mechanisms.
This study aims to assess the effectiveness of a hemp-containing cream in comparison to a
placebo for treating uremic pruritus among hemodialysis patients.